Last updated on April 2019

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: ESSENTIAL THROMBOCYTHEMIA
  • Age: Between 19 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with essential thrombocythemia according to WHO 2008
  • Any of the following as high-risk patient
  • Over 60 years old
  • >100 X 10^4/ul of platelet count
  • increased more than 300K of platelet count in 3 months
  • Hypertension, diabetes, past history of thromboembolic bleeding

Exclusion Criteria:

  • Patients with an adverse drug reaction or intolerability to anagrelide
  • Any of the following cardiac abnormalities;
  • Complete left bundle branch block on ECG
  • Patients using a pacemaker
  • Patients with a family history of congenital QT prolongation syndrome or known QT prolongation syndrome
  • Currently, there is no clinically uncontrolled ventricular or atrial tachycardia
  • Clinically significant bradycardia (<less than 50 per minute)
  • History of clinically proven myocardial infarction and unstable angina within 3 months
  • Pregnant women, nursing mothers

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.